Pauline Roche
Overview
Explore the profile of Pauline Roche including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Collomb E, Bourguignon L, Tichadou A, Roche P, Berton G, Ciccolini J, et al.
Hematol Oncol
. 2025 Mar;
43(2):e70057.
PMID: 40088477
No abstract available.
2.
Maroselli P, Fanciullino R, Colle J, Farnault L, Roche P, Venton G, et al.
Fundam Clin Pharmacol
. 2025 Jan;
39(1):e13049.
PMID: 39749370
Background: Imatinib is the treatment of elderly or frail patients with chronic myeloid leukemia (CML). Trough levels of around 1000 ng/ml are considered as the target exposure. Objectives: We searched...
3.
Prange S, Laurencin C, Roche P, Quadrio I, Thobois S
Mov Disord Clin Pract
. 2024 Jan;
11(3):303-305.
PMID: 38173343
No abstract available.
4.
Berton G, Arcani R, Tichadou A, Farnault L, Roche P, Colle J, et al.
Leuk Lymphoma
. 2023 Apr;
64(7):1355-1357.
PMID: 37042674
No abstract available.
5.
Pons N, Fernandez-Eulate G, Pegat A, Theaudin M, Guieu R, Ripellino P, et al.
Eur J Neurol
. 2023 Mar;
30(7):2001-2011.
PMID: 36943151
Background And Purpose: Biallelic variants in SORD have been reported as one of the main recessive causes for hereditary peripheral neuropathies such as Charcot-Marie-Tooth disease type 2 (CMT2) and distal...
6.
Abbou N, Piazzola P, Gabert J, Ernest V, Arcani R, Couderc A, et al.
Cells
. 2023 Jan;
12(1).
PMID: 36611899
-negative myeloproliferative neoplasms (MPNs) include three major subgroups-polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)-which are characterized by aberrant hematopoietic proliferation with an increased risk of leukemic transformation....
7.
Roche P, Venton G, Berda-Haddad Y, Fritz S, Ivanov V, Mercier C, et al.
Eur J Haematol
. 2021 Jan;
106(4):589-592.
PMID: 33469987
No abstract available.
8.
Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients
Venton G, Turcanu M, Colle J, Thuny F, Chebrek S, Farnault L, et al.
Eur J Intern Med
. 2019 Aug;
68:71-75.
PMID: 31421946
Background: Chronic myeloproliferative neoplasms (MPN) are recognized as a cause of pulmonary hypertension (pH). We ought to describe the prevalence and characteristics of PH in a cohort of MPN who...
9.
Arcani R, Venton G, Colle J, Suchon P, Ivanov V, Mercier C, et al.
Eur J Haematol
. 2019 Jul;
103(4):385-392.
PMID: 31319001
Objectives: Recently, phase III trials assessed a new combination of lenalidomide, bortezomib, and dexamethasone (RVD) in induction therapy in transplantation-eligible multiple myeloma (MM) patients, before consolidation with RVD and lenalidomide...
10.
Zordan C, Monteil L, Haquet E, Cordier C, Toussaint E, Roche P, et al.
J Community Genet
. 2019 Mar;
10(4):489-499.
PMID: 30919323
The 2011 French Bioethics Law regarding disclosure of genetic information within families enables health professionals to notify any at-risk relatives directly, with the patient's consent, using a template letter. To...